Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15426422 | 0.76 | HCRTR1 (0.51) | HCRTR1HCRTR2GPR119 | |
| SCHEMBL12626970 | 0.75 | USP2 (0.48) | HCRTR1HCRTR2GPR119USP2SMN1; SMN2 | |
| SCHEMBL12627185 | 0.75 | HCRTR1 (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL12655883 | 0.75 | HCRTR1 (0.50) | HCRTR1HCRTR2GPR119 | |
| SCHEMBL12656193 | 0.74 | L3MBTL1 (0.57) | HCRTR1HCRTR2GPR119 | |
| SCHEMBL12627108 | 0.73 | HCRTR1 (0.48) | HCRTR1HCRTR2GPR119 | |
| SCHEMBL15426424 | 0.73 | HCRTR1 (0.48) | HCRTR1HCRTR2 | |
| SCHEMBL12623931 | 0.73 | HCRTR1 (0.48) | HCRTR1HCRTR2GPR119 | |
| SCHEMBL12626973 | 0.73 | USP2 (0.46) | HCRTR1HCRTR2GPR119USP2SMN1; SMN2 | |
| SCHEMBL12626975 | 0.72 | USP2 (0.44) | HCRTR1HCRTR2GPR119USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3791875-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | Pain Therapeutics, Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3054956-B1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS INC (US) | 2020-08-26 | — | — | EP | disclosed |